Librela 20mg is a new injecton used for arthritis pain relief in dogs. Librela is scientifically proven to ease pain effectively for an entire month. With minimal liver, kidney, and GI involvement, Librela's monoclonal antibodies offer a safer, more natural approach to treating osteoarthritis in dogs.
Librela provides an innovative alternative to NSAIDs by targeting the Nerve Growth Factor (NGF), known for inducing pain and inflammation in osteoarthritis. Dogs show a marked increase in mobility and reduction in pain after the first dose, making it an ideal choice for pain management. Librela is administered as a subcutaneous injection, usually once a month, by a veterinary surgeon or at home if your Vet has given you some training.
Librela is a refrigerated medication - We will send it via Royal Mail Special Delivery using insulated packaging and ice packs. A signature is required on delivery and it must be put straight into a fridge. We cannot guarantee same day dispatch for orders placed after 12pm. VETERINARY PRESCRIPTION REQUIRED.
Librela 20mg is a caninised monoclonal antibody. Each vial of 1ml Librela contains 20mg bedinvetmab and enhances the natural process of clearing away immune complexes, thus avoiding pain signals from reaching the brain and causing neuropathic pain.
Osteoarthritis, often referred to as arthritis, is a long-term joint condition that causes pain, stiffness and reduced mobility. Dogs may find it harder to rise after rest, climb stairs, jump into the car, or keep up on walks. Managing pain can help maintain activity and muscle, which supports joint function.
Osteoarthritis commonly affects weight-bearing joints such as hips, elbows and knees, but it can also involve the spine. When a dog moves less due to pain, muscle support reduces and joints can become stiffer, which may worsen the cycle of discomfort. For this reason, long-term management often focuses on keeping movement comfortable and consistent, rather than waiting until a dog is severely lame.
How 20mg Librela works
Librela contains bedinvetmab, a canine monoclonal antibody. A monoclonal antibody is a targeted protein therapy designed to bind to a specific substance in the body. Bedinvetmab targets nerve growth factor (NGF), which is involved in pain signalling and in the "turning up" of pain sensitivity.
In osteoarthritis, NGF activity around affected joints can contribute to ongoing discomfort. When bedinvetmab binds to NGF, it helps reduce NGF‑mediated signalling. This can lower pain signalling from the joint and improve comfort. Librela does not repair cartilage or reverse structural joint changes. It is intended to manage pain so that supportive measures, such as controlled exercise and weight management, are easier to maintain.